MapLight 10-Q Confirms $51.6M Q3 Loss, $463.4M Cash Through 2028
MPLT sits 22% above its 52-week low of $6.06.
Summary
MapLight's 10-Q confirms the $51.6 million Q3 loss and $463.4 million cash pile disclosed in today's 8-K, with runway through 2028 and full detail on the $140.1 million August private placement.
Key Events · Earnings and Guidance · MPLT
-
Q3 Loss Widens to $51.6M
Net loss was $51.6 million ($0.97 per share) versus $29.4 million ($37.18 per share) in Q3 2025, driven by R&D of $44.2 million and G&A of $11.1 million.
-
Cash Runway Through 2028
Cash, cash equivalents and investments totaled $463.4 million at September 30, 2026; nine-month operating cash burn was $131.7 million.
-
August Placement Terms Detailed
9,197,887 shares at $11.38 plus 3,983,168 pre-funded warrants at $11.3799 per underlying share, for $140.1 million net after $10.0 million of fees and expenses.
-
Vanderbilt License Amended
September 2026 amendment adds a $0.4 million one-time payment and revises aggregate milestones to up to $52.0 million, with sublicense revenue sharing of 2% to 50%.
Analysis · MPLT · Life Sciences
The full quarterly report backs up this morning's 8-K: a $51.6 million third-quarter loss ($0.97 per share) against $463.4 million in cash and investments that management says funds operations through 2028. The loss is wider than a year ago as R&D climbed to $44.2 million and G&A to $11.1 million, but the balance sheet removes any near-term financing pressure. The filing also details the August private placement — 9,197,887 shares at $11.38 plus 3,983,168 pre-funded warrants, $140.1 million net — and a September amendment to the Vanderbilt license that trimmed potential milestones to $52.0 million. What matters for holders is that the cash runway now extends past the key ZEPHYR-2 readout, so the story shifts from survival to clinical execution.
How filings like this one have moved
In the 30 days to Nov 15, 2026, 37.5% of the 3713 measured filings Wiseek scored 7 moved their stock by 5% or more by the next session's close. The median move was 0.00%. These are measured outcomes after filings of this importance, not a forecast for this one.
Measured one observation per ticker per day, after exclusions. Current figures: Filing Impact Tracker · open dataset
At the time of this filing, MPLT was trading at $7.37 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $402.9M. The 52-week trading range was $6.06 to $40.43. This filing was assessed with neutral market sentiment and an importance score of 7 out of 10.